NY-INNOVATIVE-HEALTH
Andrew Sealfon, Chairman and Founder of Innovative Health Sciences LLC (“IHS”), today pledged 1,000 of his company’s unique portable non-electric IV pumps to victims of the Ukraine conflict.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220314005921/en/
The Insignis™ Syringe Infusion System includes a fully mechanical, non-electric infusion pump system and dedicated flow control devices for both intravenous and subcutaneous applications. The portable system operates independent of battery or electricity, allowing it to be stockpiled, transported, and stored for emergency situations in locations where resources may be scarce or absent. The Insignis™ system has undergone extensive testing and received ISO 13485 quality management system and CE mark certification in May 2021. The CE (Conformité Européene) mark enables IHS to sell the system throughout the European Union.
Unlike other infusers, the Insignis™ system enables the rate to be titrated and adjusted easily and quickly without drip chambers or inaccurate rate controllers. It consists of:
- Mechanical 13.5psi Syringe Driver
- Intravenous Controller
- OneSett™ Subcutaneous Administration Set
This system addresses 80-90% of the needs of infusion therapy, providing simplicity, safety, versatility, and usability. In emergency situations, it may be used for:
- Hypodermoclysis (subcutaneous rehydration when intravenous access is not feasible)
- Antibiotics or antivirals
- Fluid volume assist medications
The atrocities currently taking place in Ukraine have destroyed hospitals, wards, and care centers, crippling medical efforts. Sealfon and IHS are pledging 1,000 infusion pumps to help patients receive the care they most desperately need, as well as any education needed for optimal use of the system for Ukrainian soldiers and civilians.
The 1,000 Insignis™ pumps will be available for delivery over the next 60 days, and will be provided to third party agencies and bodies serving the victims of the conflict.
Sealfon and IHS are also coordinating private donations and setting up a GoFundMe page to allow for others to contribute additional Insignis™ pumps and ancillary supplies to victims of the Ukraine conflict. For more information, contact info@innohealthsci.com or visit https://gofund.me/508a32c3 .
About Innovative Health Sciences
New York-based Innovative Health Sciences, LLC provides innovative solutions to the infusion healthcare market. IHS’ approach is patient-centric and future-oriented; our goal is to provide the highest quality of life by empowering the patient to take control of their infusion.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220314005921/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TreeFrog Therapeutics Presents Delivery Strategy for Next Generation 3D Cell Therapy Format for Parkinson’s Disease at the 28th Annual ASGCT Meeting in New Orleans13.5.2025 08:00:00 CEST | Press release
TreeFrog Therapeutics is the first company to present publicly a clinical-ready delivery strategy for 3D format microtissues in cell therapy.After four years in development, the validated device and delivery strategy overcomes challenges of 3D formats and uses existing stereotactic components to support adoption through ease of delivery education. TreeFrog Therapeutics, a French biotech specializing in cell therapy is the first company to present a clinical-ready delivery strategy for 3D microtissues cell therapy. The validated approach was demonstrated for their 3D neural microtissues cell therapy treatment for Parkinson’s disease. Parkinson’s disease is the second most common neurodegenerative disorder after Alzheimer’s disease. It is a progressive disease characterized by the loss of dopaminergic neurons with a mix of motor symptoms (bradykinesia, rigidity, resting tremor) and non-motor symptoms (cognitive deficits, mood disorders, fatigue). Current treatments provide symptomatic re
Ohana Development Launches ‘Jacob & Co. Beachfront Living by Ohana,’ A Masterpiece of Beachfront Elegance in the UAE13.5.2025 08:00:00 CEST | Press release
Valued at USD 1.3 billion, the project offers world-class amenities, including a signature Jacob & Co. ceiling art timepiece, the largest of its kind globally. Ohana Development, the leading real estate developer renowned for its luxury properties, has launched ‘Jacob & Co. Beachfront Living by Ohana’ in partnership with luxury timepiece and jewellery house Jacob & Co. The project was revealed at Emirates Palace Mandarin Oriental, Abu Dhabi. Located in Al Jurf between Dubai and Abu Dhabi, this USD 1.3 billion development blends natural surroundings with exceptional artistry and craftsmanship. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250512533615/en/ Jacob & Co. Beachfront Living by Ohana. (Photo: AETOSWire) Jacob & Co. Beachfront Living by Ohana presents 457 residences comprising of sea-view apartments, villas, penthouses, Sky Mansions, and beachfront mansions—each capturing the spirit of refined coastal living. Pentho
Azafaros Secures € 132M in Oversubscribed Series B Financing to Advance Phase 3 Clinical Programs of Innovative Therapies in Lysosomal Storage Disorders13.5.2025 07:00:00 CEST | Press release
Financing round led by Jeito Capital and co-led by Forbion Growth, with participation from Seroba, Pictet Group and other existing investorsProceeds to fund two Phase 3 pivotal programs with nizubaglustat, lead asset in Niemann-Pick disease Type C (NPC) and GM1/GM2 gangliosidoses as well as expanding the Azafaros pipeline to other indicationsNizubaglustat has been awarded Orphan Drug Designation in both the US and Europe as well as Fast-track status in the US. The company expects to initiate both Phase 3 studies later this year Azafaros, a clinical-stage company focused on developing disease-modifying therapeutics to offer new treatment options to patients with rare lysosomal storage disorders, announces the completion of an oversubscribed €132M Series B financing led by Jeito Capital, co-led by Forbion Growth and with additional participation from Seroba, Pictet Group and existing investors Forbion Ventures, Schroders Capital and BioGeneration Ventures (BGV). This financing enables Az
Presidio Investors is Pleased to Announce the Addition of Christian Schütte as Its Newest Operating Partner12.5.2025 19:04:00 CEST | Press release
Christian brings more than 20 years of global experience in investment banking, private equity, and operational leadership, with a proven track record of driving transformational growth across industries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250512473756/en/ Christian Schütte Christian began his career at J.P. Morgan in New York and London, where he worked in the M&A and Corporate Finance teams. He later joined Fortress Investment Group and was instrumental in launching its German operations. During his tenure, he helped raise over €1.5 billion in equity and managed a wide array of investments, including non-performing and performing loans, private and public companies. He went on to join EQT Group, where he focused on mid-market growth and succession investments. Notably, he led the consolidation of nine digital marketing agencies into a €100 million market leader, building one of the most comprehensive digital ma
Introducing Joblio – The Future of Ethical Recruitment12.5.2025 18:30:00 CEST | Press release
Joblio Launches to Revolutionize Ethical Recruitment and End Worker Exploitation Joblio, a global ethical recruitment platform, officially launches today to tackle the broken labor migration system—long plagued by exploitative intermediaries, high recruitment fees, and human rights abuses. With its tech-driven model, Joblio connects vetted workers with employers directly, eliminating unethical middlemen and ensuring cost-free hiring for migrant workers. Employers fund access to talent, but workers never pay—a key step in ending exploitation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250512628048/en/ A Mission Rooted in Personal Experience Joblio is led by Jon Purizhansky, a refugee-turned-entrepreneur who experienced migration challenges firsthand. Forced to flee his home country as a young man, Jon faced the uncertainty and vulnerability that millions of migrant workers still encounter today. Now a globally recognized
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom